APGE logo

Apogee Therapeutics (APGE) Company Overview

Profile

Full Name:

Apogee Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 14, 2023

Indexes:

Not included

Description:

Apogee Therapeutics (APGE) is a biotechnology company focused on developing innovative therapies for serious diseases. They aim to improve patient outcomes by creating advanced treatments that target specific health conditions, leveraging cutting-edge science and technology in their research and development efforts.

Events Calendar

Earnings

Next earnings date:

Mar 5, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 5, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 10, 25 Guggenheim
Buy
Dec 12, 24 Guggenheim
Buy
Dec 3, 24 Guggenheim
Buy
Dec 2, 24 Wedbush
Outperform
Nov 27, 24 Guggenheim
Buy
Nov 25, 24 Canaccord Genuity
Buy
Oct 25, 24 Wedbush
Outperform
May 10, 24 B of A Securities
Buy
Mar 6, 24 Jefferies
Buy
Mar 5, 24 Stifel
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Apogee Therapeutics?
  • Does Apogee Therapeutics pay dividends?
  • What sector is Apogee Therapeutics in?
  • What industry is Apogee Therapeutics in?
  • What country is Apogee Therapeutics based in?
  • When did Apogee Therapeutics go public?
  • Is Apogee Therapeutics in the S&P 500?
  • Is Apogee Therapeutics in the NASDAQ 100?
  • Is Apogee Therapeutics in the Dow Jones?
  • When was Apogee Therapeutics's last earnings report?
  • When does Apogee Therapeutics report earnings?
  • Should I buy Apogee Therapeutics stock now?

What is the ticker symbol for Apogee Therapeutics?

The ticker symbol for Apogee Therapeutics is NASDAQ:APGE

Does Apogee Therapeutics pay dividends?

No, Apogee Therapeutics does not pay dividends

What sector is Apogee Therapeutics in?

Apogee Therapeutics is in the Healthcare sector

What industry is Apogee Therapeutics in?

Apogee Therapeutics is in the Biotechnology industry

What country is Apogee Therapeutics based in?

Apogee Therapeutics is headquartered in United States

When did Apogee Therapeutics go public?

Apogee Therapeutics's initial public offering (IPO) was on July 14, 2023

Is Apogee Therapeutics in the S&P 500?

No, Apogee Therapeutics is not included in the S&P 500 index

Is Apogee Therapeutics in the NASDAQ 100?

No, Apogee Therapeutics is not included in the NASDAQ 100 index

Is Apogee Therapeutics in the Dow Jones?

No, Apogee Therapeutics is not included in the Dow Jones index

When was Apogee Therapeutics's last earnings report?

Apogee Therapeutics's most recent earnings report was on Nov 12, 2024

When does Apogee Therapeutics report earnings?

The next expected earnings date for Apogee Therapeutics is Mar 5, 2025

Should I buy Apogee Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions